Nuvectis Pharma to Participate in the 37th Annual Roth Conference

GlobeNewswire

03-14

FORT LEE, NJ, March 14, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will participate in a fireside chat at the 37th Annual Roth Conference taking place March 17^th-19^th in Dana Point, California.

Event	37th Annual Roth Conference
Date	March 17, 2025
Time	2:30 PM Pacific Time
Link	https://event.summitcast.com/view/YsA9Ty4sRyad4m3F6KNZ7x/PL5B4myr3WCu9J7XMPKBt7

About Nuvectis Pharma

Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two clinical-stage drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule GCN2 activator currently in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an Investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. NXP900's unique mechanism of action enables the inhibition of both the catalytic and scaffolding functions of the SRC kinase thereby providing complete shutdown of the signaling pathway. NXP900 is currently in a Phase 1a dose escalation study.

Nuvectis Pharma Contact

Ron Bentsur
Chairman, Chief Executive Officer and President
rbentsur@nuvectis.com

Media Relations Contact

Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2519809873"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2519809873\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2519809873?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-14 20:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2519809873","market":"nz","top_or_hot":-1,"title":"Nuvectis Pharma to Participate in the 37th Annual Roth Conference","media":"GlobeNewswire","content":"<html><body><img hspace=\"5\" src=\"https://s1.yimg.com/uu/api/res/1.2/wYoa50Ra8UzJ2WNjlsydcw--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/globenewswire.com/989394dc1a2c2d302d391f5a4d69410d\" title=\"NuvectisPharma_Logos_FINAL_Full_Color.png\" vspace=\"5\"/>\n<p>FORT LEE, NJ, March 14, 2025 (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/NVCT\">Nuvectis Pharma, Inc.</a> (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will participate in a fireside chat at the 37th Annual Roth Conference taking place March 17<sup>th</sup>-19<sup>th</sup> in Dana Point, California.</p>\n<table>\n<tbody>\n<tr>\n<td>Event</td>\n<td>37th Annual Roth Conference</td>\n</tr>\n<tr>\n<td>Date</td>\n<td>March 17, 2025</td>\n</tr>\n<tr>\n<td>Time</td>\n<td>2:30 PM Pacific Time </td>\n</tr>\n<tr>\n<td>Link</td>\n<td>https://event.summitcast.com/view/YsA9Ty4sRyad4m3F6KNZ7x/PL5B4myr3WCu9J7XMPKBt7<br/></td>\n</tr>\n</tbody>\n</table>\n<p><b>About Nuvectis Pharma </b></p>\n<p>Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two clinical-stage drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule GCN2 activator currently in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an Investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. NXP900's unique mechanism of action enables the inhibition of both the catalytic and scaffolding functions of the SRC kinase thereby providing complete shutdown of the signaling pathway. NXP900 is currently in a Phase 1a dose escalation study. </p>\n<p><b>Nuvectis Pharma Contact</b></p>\n<p>Ron Bentsur<br/> Chairman, Chief Executive Officer and President <br/> rbentsur@nuvectis.com<br/><br/><br/></p>\n<p><b>Media Relations Contact</b></p>\n<p>Kevin Gardner <br/> LifeSci Advisors <br/> kgardner@lifesciadvisors.com <br/><br/><br/></p>\n<br/></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nuvectis Pharma to Participate in the 37th Annual Roth Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNuvectis Pharma to Participate in the 37th Annual Roth Conference\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">GlobeNewswire</strong><span class=\"h-time small\">2025-03-14 20:00</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><img hspace=\"5\" src=\"https://s1.yimg.com/uu/api/res/1.2/wYoa50Ra8UzJ2WNjlsydcw--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/globenewswire.com/989394dc1a2c2d302d391f5a4d69410d\" title=\"NuvectisPharma_Logos_FINAL_Full_Color.png\" vspace=\"5\"/>\n<p>FORT LEE, NJ, March 14, 2025 (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/NVCT\">Nuvectis Pharma, Inc.</a> (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will participate in a fireside chat at the 37th Annual Roth Conference taking place March 17<sup>th</sup>-19<sup>th</sup> in Dana Point, California.</p>\n<table>\n<tbody>\n<tr>\n<td>Event</td>\n<td>37th Annual Roth Conference</td>\n</tr>\n<tr>\n<td>Date</td>\n<td>March 17, 2025</td>\n</tr>\n<tr>\n<td>Time</td>\n<td>2:30 PM Pacific Time </td>\n</tr>\n<tr>\n<td>Link</td>\n<td>https://event.summitcast.com/view/YsA9Ty4sRyad4m3F6KNZ7x/PL5B4myr3WCu9J7XMPKBt7<br/></td>\n</tr>\n</tbody>\n</table>\n<p><b>About Nuvectis Pharma </b></p>\n<p>Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two clinical-stage drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule GCN2 activator currently in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an Investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. NXP900's unique mechanism of action enables the inhibition of both the catalytic and scaffolding functions of the SRC kinase thereby providing complete shutdown of the signaling pathway. NXP900 is currently in a Phase 1a dose escalation study. </p>\n<p><b>Nuvectis Pharma Contact</b></p>\n<p>Ron Bentsur<br/> Chairman, Chief Executive Officer and President <br/> rbentsur@nuvectis.com<br/><br/><br/></p>\n<p><b>Media Relations Contact</b></p>\n<p>Kevin Gardner <br/> LifeSci Advisors <br/> kgardner@lifesciadvisors.com <br/><br/><br/></p>\n<br/></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://finance.yahoo.com/news/nuvectis-pharma-participate-37th-annual-120000149.html\">GlobeNewswire</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVCT","symbol_name":"Nuvectis Pharma, Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/nuvectis-pharma-participate-37th-annual-120000149.html","article_id":"2519809873","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2519809873","pubTimestamp":1741953600,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Ron Bentsur Chairman, Chief Executive Officer and President  rbentsur@nuvectis.com","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVCT":"Nuvectis Pharma, Inc.","BK4139":"生物科技"},"translate_title":"Nuvectis Pharma将参加第37届罗斯年会","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVCT":1},"content_text":"FORT LEE, NJ, March 14, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will participate in a fireside chat at the 37th Annual Roth Conference taking place March 17th-19th in Dana Point, California.\n\n\n\nEvent\n37th Annual Roth Conference\n\n\nDate\nMarch 17, 2025\n\n\nTime\n2:30 PM Pacific Time \n\n\nLink\nhttps://event.summitcast.com/view/YsA9Ty4sRyad4m3F6KNZ7x/PL5B4myr3WCu9J7XMPKBt7\n\n\n\nAbout Nuvectis Pharma \nNuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two clinical-stage drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule GCN2 activator currently in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an Investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. NXP900's unique mechanism of action enables the inhibition of both the catalytic and scaffolding functions of the SRC kinase thereby providing complete shutdown of the signaling pathway. NXP900 is currently in a Phase 1a dose escalation study. \nNuvectis Pharma Contact\nRon Bentsur Chairman, Chief Executive Officer and President  rbentsur@nuvectis.com\nMedia Relations Contact\nKevin Gardner  LifeSci Advisors  kgardner@lifesciadvisors.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}